Two medicines, side by side
Fesoterodine vs solifenacin
Fesoterodine and solifenacin are both labeled for overactive bladder. Drugs@FDA records approvals of fesoterodine since 2008 and of solifenacin since 2004. Pharmacies paid $0.794 per fesoterodine ER 4 mg tablet and $0.162 per solifenacin 10 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like.
Check it at the source: the fesoterodine FDA label on DailyMed (effective April 7, 2026); the solifenacin FDA label on DailyMed (effective February 4, 2026).
Highlights of the fesoterodine record
Fesoterodine (Toviaz) · label of April 7, 2026
Used for
From the label: indicationsToviaz is indicated for the treatment of: • Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older and weighing greater than 25 kg. […]
On the market
- Earliest approval on file
- October 31, 2008
- Generic labelers
- 11 labelers
- Pharmacy cost
- $0.794 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 2
Highlights of the solifenacin record
Solifenacin (Vesicare) · label of February 4, 2026
Used for
From the label: indicationsSolifenacin Succinate Tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Solifenacin Succinate Tablets are a muscarinic antagonist indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
On the market
- Earliest approval on file
- November 19, 2004
- Generic labelers
- 20 labelers
- Pharmacy cost
- $0.162 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 6
Source: FDA drug labels via openFDA (Fesoterodine label of April 7, 2026, Solifenacin label of February 4, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do fesoterodine and solifenacin differ on the record?
How each works, in its label's words: Fesoterodine, “Fesoterodine is a competitive muscarinic receptor antagonist.”; Solifenacin, “Solifenacin is a competitive muscarinic receptor antagonist.”
Half-life, in each label's words: Fesoterodine, “The terminal half-life of the active metabolite is approximately 4 hours following an intravenous administration.”; Solifenacin, “Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours.”
Generics: fesoterodine since 2015; solifenacin since 2014 (Drugs@FDA).
| Fesoterodine | Solifenacin | |
|---|---|---|
| Labeled for | Overactive bladder | Overactive bladder |
| Pharmacologic class | n/a | Cholinergic Muscarinic Antagonist |
| How it works (label) | Fesoterodine is a competitive muscarinic receptor antagonist. | Solifenacin is a competitive muscarinic receptor antagonist. Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of urinary bladder smooth muscle. |
| Half-life (label) | The terminal half-life of the active metabolite is approximately 4 hours following an intravenous administration. | Elimination The elimination half-life (t 1/2 ) of solifenacin following chronic dosing is approximately 45-68 hours. |
| Earliest approval on file (Drugs@FDA) | October 31, 2008 | November 19, 2004 |
| First generic approved | December 10, 2015 | April 2, 2014 |
| Generic labelers (NDC) | 11 labelers | 20 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.794 per tablet (Fesoterodine ER 4 mg tablet) | $0.162 per tablet (Solifenacin 10 mg tablet) |
| 12-month price change | -10% | -3% |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 2 | 6 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 10,773 | 1,846 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What do the labels say about using others of their kind?
Fesoterodine label, drug interactionsDRUG INTERACTIONS 7.1 Antimuscarinic Drugs Coadministration of Toviaz with other antimuscarinic agents that produce dry mouth, constipation, urinary retention, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects.
Source: FDA drug labels via openFDA
What next?
- Alternatives to fesoterodine
- every medicine labeled for the same conditions